A Phase 1b, Multi-centered, Randomized, Double-blind, Placebo-controlled, Parallel Group, Three Sequential Part Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
Latest Information Update: 06 Jan 2021
At a glance
- Drugs STMC 103H (Primary)
- Indications Allergic asthma; Allergic rhinitis; Atopic dermatitis; Food hypersensitivity; Immediate hypersensitivity
- Focus Adverse reactions; First in man
- Sponsors Siolta Therapeutics
Most Recent Events
- 06 Feb 2019 New trial record